MedTrace Logo

Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin

NCT03699332 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2019-09-13

No results posted yet for this study

Summary

Intraoperative tumor localization and resection can be enhanced using intraoperative fluorescence imaging and radiodetection. Labetuzumab specifically recognizes CEA which is is expressed on \> 95% of colorectal cancers.. Therefore Indium-111-DOTA-labetuzumab-IRDye800CW is a perfect dual-labeled antibody for dual-modality image-guided surgery in peritoneal carcinomatosis of colorectal cancer.

Conditions

Interventions

DRUG

Indium-111-DOTA-Labetuzumab-IRDye800CW injection

Tracer injection

RADIATION

SPECT/CT scan

Abdominal and thoracic SPECT/CT scan.

PROCEDURE

CRS extended with dual-modality imaging

cytoreductive surgery will be performed extended with the use of dual-modality imaging.

Sponsors & Collaborators

  • Dutch Cancer Society

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • JHW de Wilt, MD, PhD · Radboud University Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2021-03-31
Completion
2021-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03699332 on ClinicalTrials.gov